| abstract |
The invention relates particularly to peptides which are specifically capable of binding IgE antibodies and can be obtained from naturally occurring S. aureus enterotoxin B (SEB), for example. The immune-modulating properties thereof are substantially different from those of bacterial SEB. Surprisingly, the inventive peptides do not induce proliferation of T cells, as opposed to SEB. Due to their properties, said peptides are suitable for treating diseases that are characterized by an increased serum IgE level and/or an increased production of interferon gamma and for treating diseases that are characterized by an imbalance in the Th1 and Th2 response, e.g. atopic eczema, lupus erythematosus, Crohn's disease, multiple sclerosis, psoriasis, and rheumatoid arthritis. |